Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)

Supporting evidence

• Other supporting evidence

• MSD Cancer Drugs Fund termination engagement meeting  presentation (PDF 1.06 MB)

  Published:

  17 February 2021

• Cancer Drugs Fund termination engagement meeting (slide set) (PowerPoint 458 KB)

  Published:

  17 February 2021

• Public Health England's data review on pembrolizumab for treating urothelial cancer (PDF 501 KB)

  Published:

  17 February 2021